SEC Form 4 · accession 0001209191-15-086631
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gilla Kaplan
Director
Period of report
Dec 21, 2015
Accepted (ET)
Dec 22, 2015 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 21, 2015 | M | 14,464 | $16.21 | A | 102,949 | D | |
| Common StockF1 | Dec 21, 2015 | S | 14,464 | $110.62 | D | 88,485 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F2 | $16.21 | Dec 21, 2015 | M | 14,464 | D | — | Dec 29, 2015 | Common Stock | 14,464 | 0 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person pursuant to a rule 10b5-1 plan in multiple transactions at prices ranging from $109.87 to $111.53, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within
- F2The option was fully exercisable.
- F3The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.